Einzeltreffer — DigiBib

Use of allopurinol or a pharmaceutically acceptable salt thereof for the treatment or prevention of Hand Foot Skin Reaction (HFSR) induced by Multitargeted Kinase Inhibitor (MKI) therapy. The allopurinol or its salt is administered topically to the affected areas, palms and soles, preferably in the form of a cream.

Titel:	USE OF ALLOPURINOL FOR THE TREATMENT OF HAND FOOT SKIN REACTION
Link:	View record in USPTO Patent Applications (Volltext)
Veröffentlichung:	2014
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Applications Sprachen: English Document Number: 20140080845 Publication Date: March 20, 2014 Appl. No: 14/087884 Application Filed: November 22, 2013 Assignees: NOBERA PHARMA, S.L. (Madrid, ES) Claim: 1-10. (canceled) Claim: 11. A method for preventing Hand Foot Skin Reaction (HFSR) induced by Multitargeted Kinase (MKI) therapy in a patient in need thereof, comprising administering to the patient a medicament having an amount of allopurinol or a pharmaceutically acceptable salt thereof which is therapeutically effective to prevent Hand Foot Skin Reaction. Claim: 12. The method according to claim 11, wherein the HFSR is induced by sorafenib. Claim: 13. The method according to claim 11, wherein the HFSR is induced by sunitinib. Claim: 14. The method according to claim 11, wherein the medicament is administered topically to the skin. Claim: 15. The method according to claim 14, wherein the medicament is administered topically to the skin of the hands or feet. Claim: 16. The method according to claim 11, wherein the medicament is a cream. Claim: 17. The method according to claim 16, wherein the medicament is a hydrophilic cream. Claim: 18. The method according to claim 11, wherein the medicament comprises from about 1% to about 10% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof. Claim: 19. The method according to claim 18, wherein the medicament comprises from about 1% to about 5% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof. Claim: 20. The method according to claim 19, wherein the medicament comprises about 3% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof. Claim: 21. The method according to claim 12, wherein the medicament is administered topically to the skin of the hands or feet. Claim: 22. The method according to claim 13, wherein the medicament is administered topically to the skin of the hands or feet. Claim: 23. The method according to claim 12, wherein the medicament comprises from about 1% to about 10% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof. Claim: 24. The method according to claim 13, wherein the medicament comprises from about 1% to about 10% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof. Claim: 25. The method according to claim 15, wherein the medicament comprises from about 1% to about 10% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof. Claim: 26. The method according to claim 25, wherein the medicament comprises from about 1% to about 5% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof. Claim: 27. The method according to claim 26, wherein the medicament comprises about 3% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof. Claim: 28. The method according to claim 23, wherein the medicament comprises from about 1% to about 5% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof. Claim: 29. The method according to claim 24, wherein the medicament comprises from about 1% to about 5% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof. Current U.S. Class: 5142/621 Current International Class: 61

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

USE OF ALLOPURINOL FOR THE TREATMENT OF HAND FOOT SKIN REACTION